Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target

Cancer Research

Volumn 73, Issue 22, 2013, Pages 6548-6553

  Khanna, Anchit ^a   Pimanda, John E ^a   Westermarck, Jukka ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BORTEZOMIB; CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A; CHECKPOINT KINASE 1; DEATH ASSOCIATED PROTEIN KINASE; IMATINIB; MYC PROTEIN; ONCOPROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PROTEIN KINASE B; PROTEIN UNC5H2; RECEPTOR PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

DRUG ACTIVITY; ENZYME INHIBITION; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; AUTOANTIGENS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; MICE; MOLECULAR TARGETED THERAPY; NEOPLASMS; ONCOGENE PROTEINS; PROTEIN PHOSPHATASE 2;

EID: 84888337350     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1994     Document Type: Review

References (31)

1. Eifert C, Powers RS. From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets. Nat Rev Cancer 2012;12:572-8.
2. Perrotti D, Neviani P. Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol 2013;14:e229-38.
3. Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008;14:152-60.
4. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell 2007;130:51-62. (Pubitemid 47039258)
5. Soo Hoo L, Zhang JY, Chan EK. Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene 2002;21:5006-15.
6. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, et al. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 2010;29:6257-66.
7. Wang J, Li W, Li L, Yu X, Jia J, Chen C. CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol 2011. [Epub ahead of print]
8. Niemela M, Kauko O, Sihto H, Mpindi JP, Nicorici D, Pernila P, et al. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene 2012;31:4266-78.
9. Mathiasen DP, Egebjerg C, Andersen SH, Rafn B, Puustinen P, Khanna A, et al. Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. Oncogene 2012;31:390-401.
10. Bockelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, et al. Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer 2011;105:989-95.
11. Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 2009;15:5092-100.
12. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, et al. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 2011;18:857-65.
13. Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 2009;101:793-805.
14. Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood 2011;117:6660-8.
15. Xue YJ, Wu GQ, Wang XN, Zou XF, Zhang GX, Xiao RH, et al. CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma. Med Oncol 2013;30:406.
16. Laine A, Sihto H, Come C, Rosenfeldt MT, Zwolinska A, Niemela M, et al. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov 2013;3:182-97.
17. Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF. CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res 2012;14:R68.
18. Kerosuo L, Fox H, Perala N, Ahlqvist K, Suomalainen A, Westermarck J, et al. CIP2A increases self-renewal and is linked to Myc in neural progenitor cells. Differentiation 2010;80:68-77.
19. Ventela S, Come C, Makela JA, Hobbs RM, Mannermaa L, Kallajoki M, et al. CIP2A promotes proliferation of spermatogonial progenitor cells and spermatogenesis in mice. PLoS ONE 2012;7:e33209.
20. Kim JS, Kim EJ, Oh JS, Park IC, Hwang SG. CIP2A modulates cell cycle progression in human cancer cells by regulating the stability and activity of PLK1. Cancer Res 2013;73:6667-6678.
21. Vervoorts J, Luscher-Firzlaff J, Luscher B. The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem 2006;281:34725-9. (Pubitemid 46036511)
22. Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T, et al. ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS One 2011;6:e17979.
23. He H, Wu G, Li W, Cao Y, Liu Y. CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis. Diagn Mol Pathol 2012;21:143-9.
24. Wiegering A, Pfann C, Uthe FW, Otto C, Rycak L, Mäder U, et al. CIP2A influences survival in colon cancer and is critical in maintaining Myc expression. PLoS One 2013;8:e75292 (Epub ahead of print).
25. Khanna A, Kauko O, Böckelman C, Laine A, Schreck I, Partanen JI, et al. Chk1 Targeting Reactivates PP2A Tumor Suppressor Activity in Cancer Cells. Cancer Res;73:6757-6769.
26. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 2004;6:308-18. (Pubitemid 38584820)
27. Andrabi S, Gjoerup OV, Kean JA, Roberts TM, Schaffhausen B. Protein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner. Proc Natl Acad Sci U S A 2007;104:19011-6.
28. Guenebeaud C, Goldschneider D, Castets M, Guix C, Chazot G, Delloye-Bourgeois C, et al. The dependence receptor UNC5H2/B triggers apoptosis via PP2A-mediated dephosphorylation of DAP kinase. Mol Cell 2010;40:863-76.
29. Tabernero J, Shapiro GI, Lorusso PM, Cervantes A, Schwartz GK, Weiss GJ, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 2013;3:406-17.
30. Pommier Y, Marchand C. Interfacial inhibitors: targeting macromolecular complexes. Nat Rev Drug Discov 2012;11:25-36.
31. Khanna A. Regulation of Cancerous inhibitor of PP2A (CIP2A) by small molecule inhibitor for c-Jun NH2-Terminal Kinases (JNKs), SP600125, in Human Fibrosarcoma (HT1080) cells. F1000Research 2013;2:174.